<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03798626</url>
  </required_header>
  <id_info>
    <org_study_id>CVPM087A2101</org_study_id>
    <secondary_id>2018-003952-19</secondary_id>
    <nct_id>NCT03798626</nct_id>
  </id_info>
  <brief_title>Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers</brief_title>
  <official_title>Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the pharmacodynamically-active dose of gevokizumab and the
      tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of
      care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic
      gastroesophageal cancer and metastatic renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">July 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1a (Dose finding): Change in high-sensitivity C-reactive protein (hsCRP) after first dose of gevokizumab monotherapy</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Log scale change of hsCRP at Day 15 from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1b (Safety run-in): Number of dose limiting toxicities (DLTs) [mGEC &amp; mRCC]</measure>
    <time_frame>First 4 weeks of combination treatment</time_frame>
    <description>DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the beginning of treatment with gevokizumab in combination with the SOC anti-cancer therapies and meets any of the protocol specified criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1b (Safety run-in): Number of DLTs [1st line mCRC and 2nd line mCRC]</measure>
    <time_frame>First 6 weeks of combination treatment</time_frame>
    <description>DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the beginning of treatment with gevokizumab in combination with the SOC anti-cancer therapies and meets any of the protocol specified criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Expansion): Progression free survival (PFS) rate per investigator assessment using RECIST v1.1 [mGEC]</measure>
    <time_frame>24 weeks</time_frame>
    <description>PFS is defined as the time from the date of first dosing of study drug to the date of the first documented progression or death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Expansion): Progression free survival (PFS) rate per investigator assessment using RECIST v1.1 [2nd line mCRC &amp; mRCC]</measure>
    <time_frame>40 weeks</time_frame>
    <description>PFS is defined as the time from the date of first dosing of study drug to the date of the first documented progression or death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Expansion): Progression free survival (PFS) rate per investigator assessment using RECIST v1.1 [1st line mCRC]</measure>
    <time_frame>64 weeks</time_frame>
    <description>PFS is defined as the time from the date of first dosing of study drug to the date of the first documented progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Expansion): Overall response rate (ORR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ORR is defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR), according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Expansion): Duration of response (DOR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration of response is defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Expansion): Disease Control Rate (DCR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DCR is defined as the proportion of subjects with a BOR of CR, PR, or stable disease (SD), according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Expansion): Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as the time from date of first dose of study treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of gevokizumab, as monotherapy and in the combination regimens</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To characterize the pharmacokinetics of gevokizumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of bevacizumab</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To characterize the pharmacokinetics of bevacizumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of ramucirumab</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To characterize the pharmacokinetics of ramucirumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of irinotecan</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To characterize the pharmacokinetics of irinotecan therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of paclitaxel</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To characterize the pharmacokinetics of paclitaxel therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of cabozantinib</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To characterize the pharmacokinetics of cabozantinib therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anti-drug antibodies for gevokizumab in the combination regimens</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of immunogenicity for gevokizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anti-drug antibodies for bevacizumab in the combination regimens</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of immunogenicity for bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anti-drug antibodies for ramucirumab in the combination regimens</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of immunogenicity for ramucirumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Gastroesophageal Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1st line colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 1st line metastatic colorectal cancer (mCRC) with Gevokizumab, modified FOLFOX6, bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd line colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 2nd line mCRC with Gevokizumab, FOLFIRI, bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd line gastroesophageal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 2nd line metastatic gastroesophageal cancer (mGEC) with Gevokizumab, paclitaxel, ramucirumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd or 3rd line renal cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 2nd or 3rd line metastatic renal cell carcinoma (mRCC) with Gevokizumab, cabozantinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gevokizumab</intervention_name>
    <description>60 mg/mL concentration; administered intravenously (IV)</description>
    <arm_group_label>1st line colorectal cancer</arm_group_label>
    <arm_group_label>2nd line colorectal cancer</arm_group_label>
    <arm_group_label>2nd line gastroesophageal cancer</arm_group_label>
    <arm_group_label>2nd or 3rd line renal cell carcinoma</arm_group_label>
    <other_name>VPM087</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>25 mg/mL concentration; administered IV</description>
    <arm_group_label>1st line colorectal cancer</arm_group_label>
    <arm_group_label>2nd line colorectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified FOLFOX6</intervention_name>
    <description>Oxaliplatin [5 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]</description>
    <arm_group_label>1st line colorectal cancer</arm_group_label>
    <other_name>oxaliplatin, leucovorin, 5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Irinotecan [20 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]</description>
    <arm_group_label>2nd line colorectal cancer</arm_group_label>
    <other_name>irinotecan, leucovorin, 5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>10 mg/mL concentration; administered IV</description>
    <arm_group_label>2nd line gastroesophageal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>6 mg/mL concentration; administered IV</description>
    <arm_group_label>2nd line gastroesophageal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>60 mg tablet; administered orally</description>
    <arm_group_label>2nd or 3rd line renal cell carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic disease not amenable to potentially curative surgery and with available
             archival tumor tissue or fresh tumor tissue biopsy.

          -  Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST
             1.1.

        For Cohort A:

        - First line metastatic colorectal cancer.

        For Cohort B:

        - Second line metastatic colorectal cancer that has progressed on prior chemotherapy
        administered for metastatic disease and which must include a fluoropyrimidine and
        oxaliplatin.

        For Cohort C:

        - Second line metastatic gastroesophageal cancer that has progressed on prior line of
        chemotherapy administered for metastatic disease, and which must include a platinum agent
        and fluoropyrimidine doublet.

        For Cohort D:

        - Second or third line metastatic renal cell carcinoma with a clear-cell component and has
        received one or two lines of treatment for metastatic disease that included an
        anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

        For subjects starting from Part 1a in Cohorts A and B:

          -  Serum hs-CRP at screening ≥ 10 mg/L.

          -  Not requiring immediate initiation of anti-cancer therapy per investigator's best
             judgement.

        For subjects starting from Part 2 in Cohorts C and D:

        - Serum hs-CRP at screening ≥ 10 mg/L.

        Exclusion Criteria:

        For All Cohorts:

          -  Currently receiving any of the prohibited medications or has contraindications as
             outlined in the protocol.

          -  Symptomatic brain metastases or brain metastases that require directed therapy (such
             as focal radiotherapy or surgery).

          -  Suspected or proven immunocompromised state, or infections (as defined in the
             protocol).

          -  Conditions that have a high risk of clinically significant bleeding after
             administration of anti-VEGF agents.

          -  Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular
             disease.

        For Cohort D:

          -  Concomitant medications, herbal supplements, and/or fruits and their juices that are
             known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow
             therapeutic window and are predominantly metabolized through CYP3A4/5.

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             cabozantinib.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona Reg-2</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Yousef</last_name>
      <email>Yousef.Janelle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Alarcon</last_name>
      <phone>623-238-7671</phone>
      <email>calarcon@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Sunil Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Taylor-Williams</last_name>
      <phone>310-825-4493</phone>
      <email>dtaylor@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A. Wainberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Drug Ship - 4</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Nichols</last_name>
      <phone>+1 615 329 7274</phone>
      <email>Andrew.Nichols@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Johanna Chock Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <state>South Austrailia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>8330074</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464 8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto Gun</city>
        <state>Shizuoka</state>
        <zip>411 8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>gastroesophageal cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>gevokizumab</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>modified FOLFOX6</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>ramucirumab</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cabozantinib</keyword>
  <keyword>CRC</keyword>
  <keyword>GEC</keyword>
  <keyword>RCC</keyword>
  <keyword>VPM087</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

